<?xml version='1.0' encoding='utf-8'?>
<document id="30838456"><sentence text="Serotonin and Norepinephrine Reuptake Inhibitors."><entity charOffset="0-9" id="DDI-PubMed.30838456.s1.e0" text="Serotonin" /><entity charOffset="14-28" id="DDI-PubMed.30838456.s1.e1" text="Norepinephrine" /><pair ddi="false" e1="DDI-PubMed.30838456.s1.e0" e2="DDI-PubMed.30838456.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s1.e0" e2="DDI-PubMed.30838456.s1.e1" /></sentence><sentence text="This chapter covers antidepressants that fall into the class of serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors"><entity charOffset="64-73" id="DDI-PubMed.30838456.s2.e0" text="serotonin" /><entity charOffset="75-79" id="DDI-PubMed.30838456.s2.e1" text="5-HT" /><entity charOffset="85-99" id="DDI-PubMed.30838456.s2.e2" text="norepinephrine" /><entity charOffset="101-103" id="DDI-PubMed.30838456.s2.e3" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e0" e2="DDI-PubMed.30838456.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e0" e2="DDI-PubMed.30838456.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e0" e2="DDI-PubMed.30838456.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e0" e2="DDI-PubMed.30838456.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e1" e2="DDI-PubMed.30838456.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e1" e2="DDI-PubMed.30838456.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e1" e2="DDI-PubMed.30838456.s2.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e2" e2="DDI-PubMed.30838456.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s2.e2" e2="DDI-PubMed.30838456.s2.e3" /></sentence><sentence text=" That is, they bind to the 5-HT and NE transporters with varying levels of potency and binding affinity ratios"><entity charOffset="27-31" id="DDI-PubMed.30838456.s3.e0" text="5-HT" /><entity charOffset="36-39" id="DDI-PubMed.30838456.s3.e1" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s3.e0" e2="DDI-PubMed.30838456.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s3.e0" e2="DDI-PubMed.30838456.s3.e1" /></sentence><sentence text=" Unlike the selective serotonin (5-HT) reuptake inhibitors (SSRIs), most of these antidepressants have an ascending rather than a flat dose-response curve"><entity charOffset="22-31" id="DDI-PubMed.30838456.s4.e0" text="serotonin" /><entity charOffset="33-37" id="DDI-PubMed.30838456.s4.e1" text="5-HT" /><pair ddi="false" e1="DDI-PubMed.30838456.s4.e0" e2="DDI-PubMed.30838456.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s4.e0" e2="DDI-PubMed.30838456.s4.e1" /></sentence><sentence text=" The chapter provides a brief review of the chemistry, pharmacology, metabolism, safety and adverse effects, clinical use, and therapeutic indications of each antidepressant" /><sentence text=" Venlafaxine, a phenylethylamine, is a relatively weak 5-HT and weaker NE uptake inhibitor with a 30-fold difference in binding of the two transporters"><entity charOffset="1-12" id="DDI-PubMed.30838456.s6.e0" text="Venlafaxine" /><entity charOffset="16-32" id="DDI-PubMed.30838456.s6.e1" text="phenylethylamine" /><entity charOffset="55-59" id="DDI-PubMed.30838456.s6.e2" text="5-HT" /><entity charOffset="71-74" id="DDI-PubMed.30838456.s6.e3" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e0" e2="DDI-PubMed.30838456.s6.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e0" e2="DDI-PubMed.30838456.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e0" e2="DDI-PubMed.30838456.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e0" e2="DDI-PubMed.30838456.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e1" e2="DDI-PubMed.30838456.s6.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e1" e2="DDI-PubMed.30838456.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e1" e2="DDI-PubMed.30838456.s6.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e2" e2="DDI-PubMed.30838456.s6.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s6.e2" e2="DDI-PubMed.30838456.s6.e3" /></sentence><sentence text=" Therefore, the drug has a clear dose progression, with low doses predominantly binding to the 5-HT transporter and more binding of the NE transporter as the dose ascends"><entity charOffset="95-99" id="DDI-PubMed.30838456.s7.e0" text="5-HT" /><entity charOffset="136-139" id="DDI-PubMed.30838456.s7.e1" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s7.e0" e2="DDI-PubMed.30838456.s7.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s7.e0" e2="DDI-PubMed.30838456.s7.e1" /></sentence><sentence text=" Venlafaxine is metabolized to the active metabolite O-desmethylvenlafaxine (ODV; desvenlafaxine) by CYP2D6, and it therefore is subject to significant inter-individual variation in blood levels and response dependent on variations in CYP2D6 metabolism"><entity charOffset="1-12" id="DDI-PubMed.30838456.s8.e0" text="Venlafaxine" /><entity charOffset="53-75" id="DDI-PubMed.30838456.s8.e1" text="O-desmethylvenlafaxine" /><entity charOffset="82-96" id="DDI-PubMed.30838456.s8.e2" text="desvenlafaxine" /><pair ddi="false" e1="DDI-PubMed.30838456.s8.e0" e2="DDI-PubMed.30838456.s8.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s8.e0" e2="DDI-PubMed.30838456.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s8.e0" e2="DDI-PubMed.30838456.s8.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s8.e1" e2="DDI-PubMed.30838456.s8.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s8.e1" e2="DDI-PubMed.30838456.s8.e2" /></sentence><sentence text=" The half-life of venlafaxine is short at about 5 h, with the ODV metabolite being 12 h"><entity charOffset="18-29" id="DDI-PubMed.30838456.s9.e0" text="venlafaxine" /></sentence><sentence text=" Both parent compound and metabolite have low protein binding and neither inhibit CYP enzymes" /><sentence text=" Therefore, both venlafaxine and desvenlafaxine are potential options if drug-drug interactions are a concern, although venlafaxine may be subject to drug-drug interactions with CYP2D6 inhibitors"><entity charOffset="17-28" id="DDI-PubMed.30838456.s11.e0" text="venlafaxine" /><entity charOffset="33-47" id="DDI-PubMed.30838456.s11.e1" text="desvenlafaxine" /><entity charOffset="120-131" id="DDI-PubMed.30838456.s11.e2" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.30838456.s11.e0" e2="DDI-PubMed.30838456.s11.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s11.e0" e2="DDI-PubMed.30838456.s11.e1" /><pair ddi="true" e1="DDI-PubMed.30838456.s11.e0" e2="DDI-PubMed.30838456.s11.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s11.e1" e2="DDI-PubMed.30838456.s11.e1" /><pair ddi="true" e1="DDI-PubMed.30838456.s11.e1" e2="DDI-PubMed.30838456.s11.e2" /></sentence><sentence text=" At low doses, the adverse effect profile is similar to an SSRI with nausea, diarrhea, fatigue or somnolence, and sexual side effects, while venlafaxine at higher doses can produce mild increases in blood pressure, diaphoresis, tachycardia, tremors, and anxiety"><entity charOffset="141-152" id="DDI-PubMed.30838456.s12.e0" text="venlafaxine" /></sentence><sentence text=" A disadvantage of venlafaxine relative to the SSRIs is the potential for dose-dependent blood pressure elevation, most likely due to the NE reuptake inhibition caused by higher doses; however, this adverse effect is infrequently observed at doses below 225 mg per day"><entity charOffset="19-30" id="DDI-PubMed.30838456.s13.e0" text="venlafaxine" /><entity charOffset="138-148" id="DDI-PubMed.30838456.s13.e1" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s13.e0" e2="DDI-PubMed.30838456.s13.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s13.e0" e2="DDI-PubMed.30838456.s13.e1" /></sentence><sentence text=" Venlafaxine also has a number of potential advantages over the SSRIs, including an ascending dose-antidepressant response curve, with possibly greater overall efficacy at higher doses"><entity charOffset="1-12" id="DDI-PubMed.30838456.s14.e0" text="Venlafaxine" /></sentence><sentence text=" Venlafaxine is approved for MDD as well as generalized anxiety disorder, social anxiety disorder, and panic disorder"><entity charOffset="1-12" id="DDI-PubMed.30838456.s15.e0" text="Venlafaxine" /></sentence><sentence text=" Desvenlafaxine is the primary metabolite of venlafaxine, and it is also a relatively low-potency 5-HT and NE uptake inhibitor"><entity charOffset="1-15" id="DDI-PubMed.30838456.s16.e0" text="Desvenlafaxine" /><entity charOffset="45-56" id="DDI-PubMed.30838456.s16.e1" text="venlafaxine" /><entity charOffset="98-102" id="DDI-PubMed.30838456.s16.e2" text="5-HT" /><entity charOffset="107-109" id="DDI-PubMed.30838456.s16.e3" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e0" e2="DDI-PubMed.30838456.s16.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e0" e2="DDI-PubMed.30838456.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e0" e2="DDI-PubMed.30838456.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e0" e2="DDI-PubMed.30838456.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e1" e2="DDI-PubMed.30838456.s16.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e1" e2="DDI-PubMed.30838456.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e1" e2="DDI-PubMed.30838456.s16.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e2" e2="DDI-PubMed.30838456.s16.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s16.e2" e2="DDI-PubMed.30838456.s16.e3" /></sentence><sentence text=" Like venlafaxine it has a favorable drug-drug interaction profile"><entity charOffset="6-17" id="DDI-PubMed.30838456.s17.e0" text="venlafaxine" /></sentence><sentence text=" It is subject to CYP3A4 metabolism, and it is therefore vulnerable to enzyme inhibition or induction" /><sentence text=" However, the primary metabolic pathway is direct conjugation" /><sentence text=" It is approved in the narrow dose range of 50-100 mg per day" /><sentence text=" Duloxetine is a more potent 5-HT and NE reuptake inhibitor with a more balanced profile of binding at about 10:1 for 5HT and NE transporter binding"><entity charOffset="1-11" id="DDI-PubMed.30838456.s21.e0" text="Duloxetine" /><entity charOffset="29-33" id="DDI-PubMed.30838456.s21.e1" text="5-HT" /><entity charOffset="38-40" id="DDI-PubMed.30838456.s21.e2" text="NE" /><entity charOffset="126-127" id="DDI-PubMed.30838456.s21.e3" text="NE" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e0" e2="DDI-PubMed.30838456.s21.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e0" e2="DDI-PubMed.30838456.s21.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e0" e2="DDI-PubMed.30838456.s21.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e0" e2="DDI-PubMed.30838456.s21.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e1" e2="DDI-PubMed.30838456.s21.e1" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e1" e2="DDI-PubMed.30838456.s21.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e1" e2="DDI-PubMed.30838456.s21.e3" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e2" e2="DDI-PubMed.30838456.s21.e2" /><pair ddi="false" e1="DDI-PubMed.30838456.s21.e2" e2="DDI-PubMed.30838456.s21.e3" /></sentence><sentence text=" It is also a moderate inhibitor of CYP2D6, so that modest dose reductions and careful monitoring will be needed when prescribing duloxetine in combination with drugs that are preferentially metabolized by CYP2D6"><entity charOffset="130-140" id="DDI-PubMed.30838456.s22.e0" text="duloxetine" /></sentence><sentence text=" The most common side effects identified in clinical trials are nausea, dry mouth, dizziness, constipation, insomnia, asthenia, and hypertension, consistent with its mechanisms of action" /><sentence text=" Clinical trials to date have demonstrated rates of response and remission in patients with major depression that are comparable to other marketed antidepressants reviewed in this book" /><sentence text=" In addition to approval for MDD, duloxetine is approved for diabetic peripheral neuropathic pain, fibromyalgia, and musculoskeletal pain"><entity charOffset="34-44" id="DDI-PubMed.30838456.s25.e0" text="duloxetine" /></sentence><sentence text=" Milnacipran is marketed as an antidepressant in some countries, but not in the USA"><entity charOffset="1-12" id="DDI-PubMed.30838456.s26.e0" text="Milnacipran" /></sentence><sentence text=" It is approved in the USA and some other countries as a treatment for fibromyalgia" /><sentence text=" It has few pharmacokinetic and pharmacodynamic interactions with other drugs" /><sentence text=" Milnacipran has a half-life of about 10 h and therefore needs to be administered twice per day"><entity charOffset="1-12" id="DDI-PubMed.30838456.s29.e0" text="Milnacipran" /></sentence><sentence text=" It is metabolized by CYP3A4, but the major pathway for clearance is direct conjugation and renal elimination" /><sentence text=" As with other drugs in this class, dysuria is a common, troublesome, and dose-dependent adverse effect (occurring in up to 7% of patients)" /><sentence text=" High-dose milnacipran has been reported to cause blood pressure and pulse elevations"><entity charOffset="11-22" id="DDI-PubMed.30838456.s32.e0" text="milnacipran" /></sentence><sentence text=" Levomilnacipran is the levorotary enantiomer of milnacipran, and it is pharmacologically very similar to the racemic compound, although the side effects may be milder within the approved dosing range"><entity charOffset="1-16" id="DDI-PubMed.30838456.s33.e0" text="Levomilnacipran" /><entity charOffset="49-60" id="DDI-PubMed.30838456.s33.e1" text="milnacipran" /><pair ddi="false" e1="DDI-PubMed.30838456.s33.e0" e2="DDI-PubMed.30838456.s33.e0" /><pair ddi="false" e1="DDI-PubMed.30838456.s33.e0" e2="DDI-PubMed.30838456.s33.e1" /></sentence><sentence text=" As with other NE uptake inhibitors, it may increase blood pressure and pulse, although it appears to do so less than some other medications"><entity charOffset="15-25" id="DDI-PubMed.30838456.s34.e0" text="NE" /></sentence><sentence text=" All medications in the class can cause serotonin syndrome when combined with MAOIs"><entity charOffset="40-49" id="DDI-PubMed.30838456.s35.e0" text="serotonin" /></sentence><sentence text="" /></document>